Stockreport

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model 

Neumora Therapeutics, Inc.  (NMRA) 
PDF NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction  NMRA-215 demonstrated best-in-class weight loss of up to [Read more]